Aprea Therapeutics Inc./$APRE
1D1W1MYTD1Y5YMAX
Capital at risk
About Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
- Ticker
- $APRE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Doylestown, United States
- Website
- aprea.com
APRE Metrics
BasicAdvanced
$9.4M
-
-$0.60
1.59
-
Price and volume
Market cap
$9.4M
Beta
1.59
52-week high
$1.69
52-week low
$0.55
Average daily volume
405K
Financial strength
Current ratio
13.554
Quick ratio
13.334
Profitability
EBITDA (TTM)
-13.201
Gross margin (TTM)
-129,523.24%
Net profit margin (TTM)
-237,362.80%
Operating margin (TTM)
-254,290.38%
Management effectiveness
Return on assets (TTM)
-27.73%
Return on equity (TTM)
-46.15%
Valuation
Price to revenue (TTM)
2,988.048
Price to book
0.24
Price to tangible book (TTM)
0.24
Price to free cash flow (TTM)
-1.269
Free cash flow yield (TTM)
-78.80%
Free cash flow per share (TTM)
-0.591
Growth
Revenue change (TTM)
-99.38%
Earnings per share change (TTM)
-74.16%
3-year revenue growth (CAGR)
-72.51%
3-year earnings per share growth (CAGR)
-50.60%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.